Loading...
New antibiotics are constantly being developed and put on the market for various indications. In this multicenter, international, industry-sponsored study, investigators compared the efficacies of the new β-lactam antibiotic, ertapenem, and ceftriaxone in 502 hospitalized, adult patients with community-acquired pneumonia (CAP).
Patients were randomized to receive intravenously 1 g/day of either ertapenem or ceftriaxone for up to 14 days. Patients with suspected Legionnaires' disease, recent antibiotic use, lung cancer, or immunocompromised states were excluded. Of the 383 evaluable patients, approximately 75% had mild-to-moderate CAP. Overall, ertapenem and ceftriaxone had similar efficacy: More than 90% of patients in both groups had a favo…